Patents by Inventor Maria Mendez-Perez

Maria Mendez-Perez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF
    Publication number: 20240109882
    Abstract: The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.
    Type: Application
    Filed: August 8, 2023
    Publication date: April 4, 2024
    Inventors: Elisabeth DEFOSSA, Uwe HEINELT, Hans MATTER, Maria MENDEZ-PEREZ, Nils RACKELMANN, Kurt RITTER, Hauke SZILLAT, Gernot ZECH
  • Isoxazolidines as RIPK1 inhibitors and use thereof
    Patent number: 11897876
    Abstract: The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: February 13, 2024
    Assignee: GENZYME CORPORATION
    Inventors: Elisabeth Defossa, Uwe Heinelt, Hans Matter, Maria Mendez-Perez, Nils Rackelmann, Kurt Ritter, Hauke Szillat, Gernot Zech
  • ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF
    Publication number: 20230219937
    Abstract: The present invention relates to isoxazolidines of formula I and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase (1) such as rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD), Crohn’s disease or ulcerative colitis.
    Type: Application
    Filed: June 1, 2021
    Publication date: July 13, 2023
    Inventors: Elisabeth DEFOSSA, Heiner GLOMBIK, Uwe HEINELT, Hans MATTER, Maria MENDEZ-PEREZ, Nils RACKELMANN, Kurt RITTER, Lothar SCHWINK, Hauke SZILLAT, Gernot ZECH
  • ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF
    Publication number: 20230203027
    Abstract: The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.
    Type: Application
    Filed: November 9, 2022
    Publication date: June 29, 2023
    Inventors: Elisabeth DEFOSSA, Uwe HEINELT, Hans MATTER, Maria MENDEZ-PEREZ, Nils RACKELMANN, Kurt RITTER, Hauke SZILLAT, Gernot ZECH
  • INSULIN CONJUGATES
    Publication number: 20220048968
    Abstract: The present invention relates to a conjugate comprising a sulfonamide of formula (I) and an active pharmaceutical ingredient such as an insulin analog comprising at least one mutation relative to the parent insulin, wherein the insulin analog comprises a mutation at position B16 which is substituted with a hydrophobic amino acid and/or a mutation at position B25 which is substituted with a hydrophobic amino acid. The present invention further relates to a sulfonamide of formula (A). Moreover, the present invention relates to an insulin analog comprising at least one mutation relative to the parent insulin.
    Type: Application
    Filed: May 25, 2021
    Publication date: February 17, 2022
    Inventors: Maria MENDEZ PEREZ, Nils RACKELMANN, Laurent BIALY, Stefan GUESSREGEN, Martin WILL, Thomas BOEHME, Ana VILLAR GAREA, Marcus Hermann KORN, Melissa BESENIUS, Jens RIEDEL, Ulrich WERNER, Michael PODESCHWA
  • Insulin conjugates
    Patent number: 11098102
    Abstract: The present invention relates to a conjugate comprising a sulfonamide of formula (I) and an active pharmaceutical ingredient such as an insulin analog comprising at least one mutation relative to the parent insulin, wherein the insulin analog comprises a mutation at position B16 which is substituted with a hydrophobic amino acid and/or a mutation at position B25 which is substituted with a hydrophobic amino acid. The present invention further relates to a sulfonamide of formula (A). Moreover, the present invention relates to an insulin analog comprising at least one mutation relative to the parent insulin.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: August 24, 2021
    Assignee: SANOFI
    Inventors: Maria Mendez Perez, Nils Rackelmann, Laurent Bialy, Stefan Guessregen, Martin Will, Thomas Boehme, Ana Villar Garea, Marcus Hermann Korn, Melissa Besenius, Jens Riedel, Ulrich Werner, Michael Podeschwa
  • Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
    Patent number: 10980816
    Abstract: The present invention relates to compounds of formula (1): wherein R6 is —CONH2 or a —C(R?)(R?)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: April 20, 2021
    Assignee: Sanofi
    Inventors: Jean-Christophe Carry, Fabienne Chatreaux, Stephanie Deprets, Olivier Duclos, Vincent Leroy, Sergio Mallart, Dominique Melon-Manguer, Maria Mendez-Perez, Fabrice Vergne
  • NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF
    Publication number: 20200323874
    Abstract: The present invention relates to compounds of formula (1): wherein R6 is —CONH2 or a —C(R?)(R?)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.
    Type: Application
    Filed: June 29, 2020
    Publication date: October 15, 2020
    Inventors: Jean-Christophe CARRY, Fabienne CHATREAUX, Stephanie DEPRETS, Olivier DUCLOS, Vincent LEROY, Sergio MALLART, Dominique MELON-MANGUER, Maria MENDEZ-PEREZ, Fabrice VERGNE
  • Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
    Patent number: 10736904
    Abstract: The present invention relates to compounds of formula (I): wherein R6 is —CONH2 or a —C(R?)(R?)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: August 11, 2020
    Assignee: SANOFI
    Inventors: Jean-Christophe Carry, Fabienne Chatreaux, Stephanie Deprets, Olivier Duclos, Vincent Leroy, Sergio Mallart, Dominique Melon-Manguer, Maria Mendez-Perez, Fabrice Vergne
  • INSULIN CONJUGATES
    Publication number: 20200181223
    Abstract: The present invention relates to a conjugate comprising a sulfonamide of formula (I) and an active pharmaceutical ingredient such as an insulin analog comprising at least one mutation relative to the parent insulin, wherein the insulin analog comprises a mutation at position B16 which is substituted with a hydrophobic amino acid and/or a mutation at position B25 which is substituted with a hydrophobic amino acid. The present invention further relates to a sulfonamide of formula (A). Moreover, the present invention relates to an insulin analog comprising at least one mutation relative to the parent insulin.
    Type: Application
    Filed: December 10, 2019
    Publication date: June 11, 2020
    Inventors: Maria MENDEZ PEREZ, Nils RACKELMANN, Laurent BIALY, Stefan GUESSREGEN, Martin WILL, Thomas BOEHME, Ana VILLAR GAREA, Marcus Hermann KORN, Melissa BESENIUS, Jens RIEDEL, Ulrich WERNER, Michael PODESCHWA
  • NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF
    Publication number: 20200078370
    Abstract: The present invention relates to compounds of formula (I): wherein R6 is —CONH2 or a —C(R?)(R?)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.
    Type: Application
    Filed: October 30, 2019
    Publication date: March 12, 2020
    Inventors: Jean-Christophe CARRY, Fabienne CHATREAUX, Stephanie DEPRETS, Olivier DUCLOS, Vincent LEROY, Sergio MALLART, Dominique MELON-MANGUER, Maria MENDEZ-PEREZ, Fabrice VERGNE
  • Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
    Patent number: 10500212
    Abstract: The present invention relates to compounds of formula (I): wherein R6 is —CONH2 or a —C(R?)(R?)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: December 10, 2019
    Assignee: SANOFI
    Inventors: Jean-Christophe Carry, Fabienne Chatreaux, Stephanie Deprets, Olivier Duclos, Vincent Leroy, Sergio Mallart, Dominique Melon-Manguer, Maria Mendez-Perez, Fabrice Vergne
  • NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF
    Publication number: 20190151330
    Abstract: The present invention relates to compounds of formula (I): wherein R6 is —CONH2 or a —C(R?)(R?)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.
    Type: Application
    Filed: January 10, 2019
    Publication date: May 23, 2019
    Inventors: Jean-Christophe CARRY, Fabienne CHATREAUX, Stephanie DEPRETS, Olivier DUCLOS, Vincent LEROY, Sergio MALLART, Dominique MELON-MANGUER, Maria MENDEZ-PEREZ, Fabrice VERGNE
  • Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
    Patent number: 10220044
    Abstract: The present invention relates to compounds of formula (I): wherein R6 is —CONH2 or a —C(R?)(R?)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: March 5, 2019
    Assignee: SANOFI
    Inventors: Jean-Christophe Carry, Fabienne Chatreaux, Stephanie Deprets, Olivier Duclos, Vincent Leroy, Sergio Mallart, Dominique Melon-Manguer, Maria Mendez-Perez, Fabrice Vergne
  • NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF
    Publication number: 20170319594
    Abstract: The present invention relates to compounds of formula (I): wherein R6 is —CONH2 or a —C(R?)(R?)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.
    Type: Application
    Filed: July 26, 2017
    Publication date: November 9, 2017
    Inventors: Jean-Christophe CARRY, Fabienne CHATREAUX, Stephanie DEPRETS, Olivier DUCLOS, Vincent LEROY, Sergio MALLART, Dominique MELON-MANGUER, Maria MENDEZ-PEREZ, Fabrice VERGNE
  • Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase
    Patent number: 9776991
    Abstract: The present invention relates to compounds of the formula (I), wherein R1, R2, R3, R4 and X have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They are highly potent and selective soluble epoxide hydrolase inhibitors and are suitable, for example, for the therapy and prophylaxis of renal failure, diabetic nephropathy, type 2 diabetes mellitus, cardiovascular diseases, inflammatory diseases or could show beneficial effects in pain, dyslipidemia, atherosclerosis wound healing and stroke. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: October 3, 2017
    Assignee: SANOFI
    Inventors: Maria Mendez-Perez, Kristin Breitschopf, Katrin Lorenz, Hartmut Strobel, Li-hsing Wang, Alexander Schiffer, Jochen Goerlitzer
  • Therapeutic uses of novel thienopyrimidine derivatives
    Patent number: 9744176
    Abstract: The present invention relates to therapeutic uses of the compounds of formula (I): wherein R6 is —CONH2 or a —C(R?)(R?)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: August 29, 2017
    Assignee: SANOFI
    Inventors: Jean-Christophe Carry, Fabienne Chatreaux, Stephanie Deprets, Olivier Duclos, Vincent Leroy, Sergio Mallart, Maria Mendez-Perez, Fabrice Vergne
  • Isomannide derivatives as inhibitors of soluble epoxide hydrolase
    Patent number: 9540391
    Abstract: The present invention relates to compounds of the formula (I), wherein R1, R11, R12 and X have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They are highly potent and selective soluble epoxide hydrolase inhibitors and are suitable, for example, for the therapy and prophylaxis of renal failure, diabetic nephropathy, type 2 diabetes mellitus, inflammation or could show beneficial effects in pain, dyslipidemia and atherosclerosis. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: January 10, 2017
    Assignee: SANOFI
    Inventors: Katrin Lorenz, Kristin Breitschopf, Hartmut Strobel, Maria Mendez-Perez, Li-hsing Wang, Alexander Schiffer, Joseph T. Kim, Hans-Peter Nestler, Mark Drew
  • THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE
    Publication number: 20160326146
    Abstract: The present invention relates to compounds of the formula (I), wherein R1, R2, R3, R4 and X have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They are highly potent and selective soluble epoxide hydrolase inhibitors and are suitable, for example, for the therapy and prophylaxis of renal failure, diabetic nephropathy, type 2 diabetes mellitus, cardiovascular diseases, inflammatory diseases or could show beneficial effects in pain, dyslipidemia, atherosclerosis wound healing and stroke. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Application
    Filed: December 2, 2014
    Publication date: November 10, 2016
    Inventors: Maria MENDEZ-PEREZ, Kristin BREITSCHOPF, Katrin LORENZ, Hartmut STROBEL, Li-hsing WANG, Alexander SCHIFFER, Jochen GOERLITZER
  • NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF
    Publication number: 20150352124
    Abstract: The present invention relates to therapeutic uses of the compounds of formula (I): wherein R6 is —CONH2 or a —C(R?)(R?)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group.
    Type: Application
    Filed: July 8, 2015
    Publication date: December 10, 2015
    Inventors: Jean-Christophe CARRY, Fabienne CHATREAUX, Stephanie DEPRETS, Olivier DUCLOS, Vincent LEROY, Sergio MALLART, Dominique MELON-MANGUER, Maria MENDEZ-PEREZ, Fabrice VERGNE